Shares of Transcat, Inc. (NASDAQ:TRNS) have earned a consensus broker rating score of 1.50 (Buy) from the two brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. Transcat’s rating score has improved by 25% from three months ago as a result of a number of analysts’ upgrades and downgrades.
Brokerages have set a 12-month consensus price target of $34.75 for the company and are expecting that the company will post $0.26 earnings per share for the current quarter, according to Zacks. Zacks has also given Transcat an industry rank of 72 out of 255 based on the ratings given to its competitors.
A number of brokerages have commented on TRNS. Zacks Investment Research downgraded shares of Transcat from a “buy” rating to a “hold” rating in a research note on Saturday, October 26th. ValuEngine lowered shares of Transcat from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Roth Capital began coverage on shares of Transcat in a research note on Thursday, October 31st. They issued a “buy” rating and a $34.50 price target for the company. Finally, Dougherty & Co raised their price target on shares of Transcat from $32.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 24th.
Transcat (NASDAQ:TRNS) last posted its quarterly earnings results on Wednesday, October 23rd. The scientific and technical instruments company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.20 by $0.12. Transcat had a return on equity of 13.91% and a net margin of 4.91%. The business had revenue of $41.76 million for the quarter. On average, equities analysts anticipate that Transcat will post 1.09 earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of the business. Marshall Wace North America L.P. raised its position in Transcat by 157.5% in the first quarter. Marshall Wace North America L.P. now owns 1,545 shares of the scientific and technical instruments company’s stock valued at $36,000 after purchasing an additional 945 shares during the period. Strs Ohio purchased a new stake in Transcat in the 2nd quarter valued at about $46,000. Hillsdale Investment Management Inc. purchased a new stake in Transcat in the 2nd quarter valued at about $102,000. Oppenheimer Asset Management Inc. lifted its position in Transcat by 112.9% in the second quarter. Oppenheimer Asset Management Inc. now owns 5,788 shares of the scientific and technical instruments company’s stock valued at $148,000 after buying an additional 3,069 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. acquired a new position in Transcat in the second quarter valued at about $414,000. 62.08% of the stock is owned by institutional investors.
Transcat Company Profile
Transcat, Inc provides calibration and laboratory instrument services in North America and internationally. It operates in two segments, Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.
Recommended Story: How Do You Calculate Return on Equity (ROE)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Transcat Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transcat and related companies with MarketBeat.com's FREE daily email newsletter.